Recently, the International Agency for Research on Cancer (IARC) of the World Health Organization released the latest data about the global cancer burden in 2020. The number of confirmed gastric cancer (GC) cases in the world is 1.09 million, accounting for 5.6% and ranking the fifth among all cancers. Immunotherapy has ushered in an era of precision treatment.[1] K e y n o t e 0 5 9 [ 2 ] , K e y n o t e 0 6 1 [ 3 ] , Keynote-062, attraction-02[4], and other studies have repeatedly verified the effectiveness of PD-1 therapy. In addition, ANTXR1, IDO1, TIM-3, and LAG-3 have been found as functional biomarkers similar to PD-1, and their expression was related to the overall survival.[5] Therefore, these biomarkers are likely to brew new precision treatments for GC in the future.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: